Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction

Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor is a recently introduced oral medication to treat renal anemia, but its clinical implication in patients with heart failure, particularly heart failure with preserved ejection fraction (HFpEF), remains unknown. We had a 91-year-old woman...

Descripción completa

Detalles Bibliográficos
Autores principales: Imamura, Teruhiko, Hori, Masakazu, Tanaka, Shuhei, Kinugawa, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705005/
https://www.ncbi.nlm.nih.gov/pubmed/34946264
http://dx.doi.org/10.3390/medicina57121319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705005/
https://www.ncbi.nlm.nih.gov/pubmed/34946264
http://dx.doi.org/10.3390/medicina57121319

Ejemplares similares